title: The effect of granulocyte-colony stimulating factor on endothelial function in patients with myocardial infarction.
abstract: OBJECTIVE
  The effects of granulocyte-colony stimulating factor (G-CSF) on endothelial function are unknown. Therefore, we investigated the effects of G-CSF on endothelial function.
  
  
  METHODS
  76 patients participating in the MAGIC-Cell-3-DES trial were enrolled. These were patients with acute myocardial infarction (AMI) or old MI (OMI) who underwent percutaneous coronary intervention (PCI), and were prospectively randomised into a G-CSF group (G-CSF (10 microg/kg/day) injection for 3 days after PCI) or a control group. Additionally, 20 healthy volunteers were also enrolled. These subjects were categorised into five groups: AMI-control (n = 18), AMI-G-CSF (18), OMI-control (20), OMI-G-CSF (20) and healthy-G-CSF (20). Baseline flow-mediated dilation (FMD) of the brachial artery and serum inflammatory biomarkers were performed on day 1, and repeated on day 4 in all groups. G-CSF was injected for 3 days between days 1 and 4 in the AMI-G-CSF, OMI-G-CSF and healthy-G-CSF groups.
  
  
  RESULTS
  In both the healthy-G-CSF and OMI-G-CSF groups, G-CSF increased serum high sensitivity C-reactive protein (hsCRP) (0.3 (0.5) mg/l vs 6.1 (3.5) mg/l and 5.6 (3.8) mg/l vs 13.0 (7.7) mg/l, baseline vs post-G-CSF in the healthy and OMI-G-CSF groups, respectively, p<0.001). In the AMI-G-CSF group, G-CSF hindered the decline of hsCRP during the recovery phase, resulting in a relative increase in hsCRP. However, in all three groups, G-CSF did not significantly alter FMD.
  
  
  CONCLUSIONS
  Despite an associated increase in systemic inflammation, G-CSF treatment does not lead to acute impairment of brachial artery endothelial function in either healthy subjects or patients with MI.
authors.affiliation: Department of Internal Medicine, Seoul National University College of Medicine: Innovative Research Institute for Cell Therapy, Seoul National University Hospital, Chongno-gu, Seoul, Korea.
authors.forename: Y-J
authors.initials: YJ
authors.lastname: Kim
authors.forename: J-I
authors.initials: JI
authors.lastname: Shin
authors.forename: K-W
authors.initials: KW
authors.lastname: Park
authors.forename: H-Y
authors.initials: HY
authors.lastname: Lee
authors.forename: H-J
authors.initials: HJ
authors.lastname: Kang
authors.forename: B-K
authors.initials: BK
authors.lastname: Koo
authors.forename: B-J
authors.initials: BJ
authors.lastname: Park
authors.forename: D-W
authors.initials: DW
authors.lastname: Sohn
authors.forename: B-H
authors.initials: BH
authors.lastname: Oh
authors.forename: Y-B
authors.initials: YB
authors.lastname: Park
authors.forename: H-S
authors.initials: HS
authors.lastname: Kim
mesh_terms: D000328:Adult; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers; D001916:Brachial Artery / Q000187:drug effects* / Q000502:physiology; D016207:Cytokines / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000502:physiology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy*; D011446:Prospective Studies
chemical_list: D015415:Biomarkers; D016207:Cytokines; D016179:Granulocyte Colony-Stimulating Factor